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ABSTRACT
Nuclear receptors (NRs) regulate gene expression
by binding specific DNA sequences consisting of
AG[G/T]TCA or AGAACA half site motifs in a
variety of configurations. However, those motifs/
configurations alone do not adequately explain the
diversity of NR function in vivo. Here, a systematic
examination of DNA binding specificity by protein-
binding microarrays (PBMs) of three closely related
human NRs—HNF4a, retinoid X receptor alpha
(RXRa) and COUPTF2—reveals an HNF4-specific
binding motif (H4-SBM), xxxxCAAAGTCCA, as well
as a previously unrecognized polarity in the clas-
sical DR1 motif (AGGTCAxAGGTCA) for HNF4a,
RXRa and COUPTF2 homodimers. ChIP-seq data
indicate that the H4-SBM is uniquely bound by
HNF4a but not 10 other NRs in vivo, while NRs
PXR, FXRa, Rev-Erba appear to bind adjacent to
H4-SBMs. HNF4-specific DNA recognition and
transactivation are mediated by residues Asp69
and Arg76 in the DNA-binding domain; this combin-
ation of amino acids is unique to HNF4 among all
human NRs. Expression profiling and ChIP data
predict  100 new human HNF4a target genes with
an H4-SBM site, including several Co-enzyme
A-related genes and genes with links to disease.
These results provide important new insights into
NR DNA binding.
INTRODUCTION
Nuclear receptors (NRs) are ligand-dependent transcrip-
tion factors (TFs) that play important roles in nearly every
aspect of human physiology (1). They are linked to human
disease, are popular drug targets and play a major role in
regulating the expression of genes responsible for drug
metabolism (2–4). Therefore, proper elucidation of their
target genes has important clinical ramiﬁcations. NRs
regulate gene expression primarily by ﬁrst binding
speciﬁc DNA response elements in the regulatory regions
of target genes. Basic rules for NR DNA binding that
consist of distinct half sites motifs for steroid (AGAACA
) and non-steroid (AGGTCA) receptors and half site con-
ﬁgurations—direct (DR, !!), inverted (IR, ! ),
everted repeats (ER, ! ) and non-repeats (nRs) as well
as spacing between the repeats—were established early
on (5–8). This dogma, the ‘DR rule’, successfully drove
the identiﬁcation of individual NR target genes in the
pre-genomic era. However, there remains considerable
overlap in the apparent binding speciﬁcity of many NRs,
which could be due to the high degree of conservation
among the NR DNA-binding domains (DBDs) and/or to
the fact that NR DNA binding speciﬁcity has not been
analyzed in a systematic, global fashion.
The magnitude of the complexity and intricacy of
DNA binding speciﬁcity is illustrated by the fact that
for a 13-nt-long motif, such as a direct repeat of AGGT
CA with a spacing of 1nt (DR1, AGGTCAxAGGTCA),
there are 4
13/2 ( 34 million) different potential DNA
sequences. If a given NR binds just 0.01% of those
sites for a speciﬁcity of 1 in 10000, that still yields 3400
unique sequences, all of which could have just a minor
variation on the DR1 consensus. The question then
arises as to how many of those different sequences will
bind a given NR and whether there are motifs speciﬁc to
different NRs.
There are three well-characterized subfamilies of recep-
tors that bind DR1s as homodimers—HNF4a (NR2A1),
COUPTF2 (NR2F2) and RXRa (NR2B1). They are all
very highly conserved, closely related and regulate a
variety of metabolic genes in common tissues such as
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activator that binds an endogenous ligand (linoleic acid)
(11). It is considered to be a master regulator of
liver-speciﬁc gene expression, including genes involved in
intermediary metabolism as well as xenobiotic and drug
metabolism (12–15). HNF4a is linked to several human
diseases including diabetes, hemophilia, hepatitis, athero-
sclerosis and inﬂammatory bowel disease (16,17).
RXRa is also expressed primarily in the liver, as well as
kidney, gut, muscle and skin (10). While it is best known
as a heterodimeric partner of other NRs such as PPAR
(NR1C), RAR (NR1B), FXR (NR1H), PXR (NR1I2),
TR (NR1A) and VDR (NR1I1) (7,18), it binds directly
to the synthetic ligand 9-cis retinoid acid and has been
shown to activate transcription in the absence of an
ectopically expressed partner (19–23). COUPTF2 is also
present in the liver and, like RXRa, is fairly ubiquitously
expressed. However, it acts primarily as a repressor of
transcription (24,25); it remains an orphan receptor in
that its endogenous ligand has not yet been identiﬁed,
although it has been shown to bind and respond to retin-
oids (26). Like HNF4a, COUPTF2 binds DNA well as a
homodimer but unlike HNF4a it can also heterodimerize
with RXRa (21,25,27). It was recognized early on that
HNF4a, RXRa and COUPTF2 all share common
binding sites (that roughly resemble DR1s) in the pro-
moters of certain genes and consequently compete for
regulation of those genes (28–30). However, it was also
noted that there are a couple of binding sites in other
genes that were not bound by all three NRs (28,31,32).
While these results suggested the existence of NR-speciﬁc
binding motifs, common versus unique binding features
were never identiﬁed and the extent of the overlap
remained obscure.
New genome-scale technologies, both in vivo and
in vitro, now allow us to address the issue of NR
binding speciﬁcity in an appropriately global fashion
(33). For in vivo binding, chromatin immunoprecipitation
followed by deep sequencing (ChIP-seq) enables robust
and accurate identiﬁcation of TF binding regions, but
the resolution is not sufﬁcient to identify the exact site
to which TFs bind; this must be done by statistical infer-
ence (34). For in vitro binding, protein-binding micro-
arrays (PBMs), can assay the binding of TFs to 10000s
of DNA probes in a high throughput fashion (35).
PBM data are extremely useful for mining ChIP-seq
data to identify the precise location of TF binding and
to predict new target genes by cross-referencing. We
recently applied a modiﬁed PBM approach to HNF4a
and identiﬁed 100s of new direct targets of HNF4a by
combining the PBM results with genome-wide location
and expression proﬁling data (13).
Here, we apply the PBM approach to the problem
of distinguishing the binding speciﬁcity of HNF4a,
RXRa and COUPTF2. We show that RXRa homodimers
bind DNA very well in the PBM and that they have a spe-
ciﬁcity nearly identical to COUPTF2 homodimers, with a
clear preference for the 30 half site of a DR1 motif. The
PBMs also identiﬁed an HNF4a-speciﬁc binding motif
(H4-SBM) (CAAAGTCCA) that was veriﬁed in vivo in
ChIP-seq data. Finally, we determine the amino acid
residues in the HNF4a DBD (Asp69 and Arg76) respon-
sible for the unique binding speciﬁcity of HNF4a and
identify  100 new human target genes that contain the
HNF4–speciﬁc motif. These results have important impli-
cations not just for HNF4a, RXRa and COUPTF2, but
for the entire NR superfamily as well.
MATERIALS AND METHODS
PBM design, assay and data processing
Two different custom arrays in 8 15k format ordered
from Agilent Technologies (Santa Clara, CA, USA)
were used to test binding speciﬁcity (PBM2) (13)
and half site preferences (PBM6.1) (see Supplementary
Figure S2 for design and Supplementary Table S4 for
complete sequences of PBM6.1). Each of the  3000 se-
quences was spotted four (PBM6.1) to ﬁve (PBM2)
times in each of the eight grids. The PBM assay was per-
formed as previously described (13) with minor modiﬁca-
tions: 1.6mM Cy5 dUTPs (Enzo Life Sciences) was
used to label the double-stranded DNA on the slide;
 0.8–1.2mg of each full length NR in crude nuclear
extracts from transfected Cos-7 cells was applied to the
PBM; and bound NRs were detected with primary
antibodies for human HNF4a, RXRa, COUPTF2 and
RARa from R&D Systems (Catalogue # PP-H1415,
PP-K8508, PP-H7147 and PP-H1920-00, respectively)
at a 1:100 dilution overnight at room temperature, and
then secondary antibody (Dam-Dylight-Cy3, Jackson
ImmunoResearch) at a 1:50 dilution for 1h. After three
washes in PBS-0.1% Tween-20, the slide was dried and
scanned at 633 (Cy5) and 543nm (Cy3). Data extrac-
tion and normalization was performed as previously
described (13). The binding threshold of each NR was
set to two SD from the mean or the quantile 0.95 of the
random controls, whichever was higher. DNA motifs (rep-
resented using position weight matrices, PWM) were
generated using SeqLogo (36) and Weblogo v2.8.2 (37).
Hypergeometric tests are performed using phyper in R.
While the HNF4a PBM2 was repeated, our previous
raw data for the HNF4a PBM2 (13) was used for
analysis since the signal intensities were closer to that of
RXRa and COUPTF2.
Motif mining of ChIP-seq peaks
DNA sequences in ChIP-seq peak regions were extracted
by Cisgenome and analyzed for relative enrichment level
(fold enrichment) compared to matched control regions as
described in (38). The length of each control region was
determined by the average length of all peaks in a data set
and the total number of control regions was ﬁve times
as many as ChIP-seq peaks. If multiple data sets were
available for an NR, the average was used as the ﬁnal
score and SD was given (Supplementary Table S1). The
empirical P value of the enrichment score for each motif
was determined using the enrichment distribution of 1000
6- or 9-nt random genomic sequences. Coordinates
of peak centers were either given in the preprocessed
BED or WIG ﬁles or obtained by reprocessing the data
(in the case of ERRb and Rev-Erba). Density plots were
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using a two-sided F-test. Motif mining was performed by
Gibbs Motif Sampler (39) implemented in Cisgenome,
using 3000 iterations and the third-order Markov Chain
model. The best AGGTCA-like motif was selected from
10 candidates with the highest scores.
Identiﬁcation of HNF4-speciﬁc target genes
DNA sequences from  10 to+10kb of each gene in
the human genome (hg19) were downloaded from the
Ensembl genome browser (http://uswest.ensembl.org/
index.html) using BioPerl API. The occurrences of
HNF4-speciﬁc binding sequences, obtained from either
the PBM data or support vector machine (SVM) predic-
tion (see details in Supplementary Data), were identiﬁed
by Seqmap (40) using exact match. A total of 3000
random 13-mers were selected randomly from the
human genome. The difference between two frequency
distributions was calculated using the Student’s t-test
in R. The online search engine for HNF4-speciﬁc
binding sequence was developed using Perl and cgi, and
is hosted by the Bioinformatics Core of Institute for
Integrative Genome Biology at University of California
at Riverside at http://nrmotif.ucr.edu/NRBSScan/
H4SBM.htm. HNF4a ChIP-seq peaks from HepG2 cells
(41) were examined and only those peaks containing
at least one HNF4-speciﬁc binding site were selected as
HNF4-speciﬁc peaks. If a gene had at least one HNF4-
speciﬁc peak within 10kb of its transcription start site
(TSS), then this gene was considered as an HNF4-
speciﬁc candidate target. Only down-regulated candidate
genes in HNF4 RNAi assay (in HepG2 cells) (13) were
chosen as ﬁnal targets. Gene Ontology (GO) analysis was
performed using DAVID (42).
RESULTS
PBMs reveal a polarity in the DR1 motif
for RXRa, COUPTF2 and HNF4a
Custom PBMs were used to examine the DNA binding
speciﬁcity of human HNF4a2 (referred to as HNF4a),
RXRa and COUPTF2. They bound 1371, 1285 and
1530 unique DNA sequences, respectively, although
there was considerable overlap, especially between
RXRa and COUPTF2 (Figure 1A). Notably, while
RXRa in the absence of a heterodimeric partner typic-
ally does not bind DNA in shift gels (22,23,27), it
bound very well in the PBM in both the presence and
the absence of its ligand 9-cis retinoid acid; control ex-
periments veriﬁed that the amount of endogenous NRs
such as RARa was too low to be detected in the PBMs
(see Supplementary Figure S1 for details and
Supplementary Table S4 for a list of all sequences).
There are reports of RXRa activating transcription or
binding DNA in the absence of added NR partners (19–
23,43–45), and recent ChIP-seq experiments reveal con-
siderable RXR binding in the absence of a PPAR
partner (46), suggesting that RXR homodimers bind
DNA in vivo as well as in vitro.
All bound sequences were ranked according to their
normalized signal intensities (binding scores) and DNA
motifs were generated for strong, medium and weak
binders [binding afﬁnity is linearly correlated with the
binding signal from PBMs (47)]. Motifs of the top 10%
Figure 1. DNA binding speciﬁcity of human HNF4a, RXRa and COUPTF2 determined by PBMs. (A) Work ﬂow and overall results of PBM
experiment. Total number of distinct DNA sequences (sites) bound by each NR is given as well as the number of overlapping and unique sequences
(Venn diagram). (B) DNA motifs for the top 10% of binders as well as top 33% (strong), middle 33% (medium) and bottom 33% (weak) of binders.
(C) Schematic representation of NR binding orientation on original and reverse complement (RC) DNA probes. Orange triangles, DBDs of 50 and 30
NR monomers. The canonical DR1 half site AGGTCA (red) is close to the free end of the original probe, while the corresponding sequence in the
RC probe is close to the slide in the PBM. (D) Motifs of the 30 strongest and 30 weakest binders of the original or RC probes for COUPTF2 as
indicated. (See Supplementary Figures S1B for the results of HNF4a and RXRa, and Figure S2A for details in probe design.).
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of the DR1 motif contain essential positions for binding,
reinforcing the notion that these three NRs bind as
homodimers on the PBM (Figure 1B). We also noted
that the strong binders for RXRa and COUPTF2 had
more conserved positions in the 30 than in the 50 half
site, suggesting that the 30 half site may be more critical
for DNA binding. Since, the 30 half site is farther from the
glass slide in the PBM, it was possible that the observed
polarity was an artifact of the PBM design. Therefore, we
designed a second PBM in which 30 strong binders of
COUPTF2 with AGGTCA half sites on the 30 side were
compared with 30 weak binders with AGGTCA on the
50 side; a third group of probes had weak AGGTCA
-like motifs in both half sites. The reverse compliment
(RC) of each probe was also examined (Supplementary
Figure S2A). If COUPTF2 DNA binding is affected by
the distance from the slide, then the RC probes of corres-
ponding strong binders will become weak binders, and
vice versa (Figure 1C). We found that the strongest
binders for both the original and the RC probes were
the same sequences with a clear preference for AGGTC
A in the 30 half site, even when it was close to the slide;
conversely, the weakest binders had the AGGTCA motif
in the 50 half site regardless of the distance to the slide
(Figure 1D). Similar results were observed for RXRa
and HNF4a (Supplementary Figure S2B). We also
examined the effect of the distance of the entire 13-mer
from the slide as well as the free end of the probe and
found that the strongest binding by all three NRs
resulted when the 13-mer is 27nt from the slide and 5nt
from the free end of the probe (Supplementary Figure S2C
and S2D). All together, these results suggest that in vitro
RXRa, COUPTF2 and HNF4a prefer the 30 half site of
the DR1 motif.
PBMs identify an HNF4a-speciﬁc binding motif
The DNA binding speciﬁcity of HNF4a, RXRa and
COUPTF2 was further analyzed using scatter plots
(Figure 2A). RXRa and COUPTF2 shared very similar
binding speciﬁcities with an R
2 of 0.84 for all bound
sequences. In contrast, HNF4a showed a different
proﬁle with >200 DNA sequences bound exclusively by
HNF4a. The consensus motif of HNF4-speciﬁc binders
had a subtle yet consistent change at position 10 (p10)
and p11, where GT was replaced by TC. Together with
seven other conserved positions, it deﬁned the HNF4-
speciﬁc binding motif (H4-SBM) xxxxCAAAGTCCA
(x refers to any nucleotide; the nucleotides that dif-
fer from the canonical AGGTCA are underlined)
(Figure 2B). Hypergeometric plots using all the binders
indicate that TC at p10–p11 are disfavored by both
RXRa and COUPTF2 (Figure 2C). Interestingly, the
probes that were bound by RXRa and COUPTF2 but
not HNF4a strongly resembled a canonical DR1 motif
(Figure 2B).
We next determined that all 81 of the PBM probes
bearing the H4-SBM were in fact HNF4-speciﬁc
binders; they all bound HNF4a but none bound
RXRa or COUTF2 (Figure 2D, left panel). There
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TCAAAGTCC A )t h a tb o u n dR X R a and COUPTF2
weakly; they are hybrids of the canonical DR1 and
the HNF4-speciﬁc half site. In contrast, the probes con-
taining AGTCCA only in the 50 half site were not com-
pletely speciﬁc for HNF4a (Figure 2D, middle panel)
while those with the canonical AGGTCA in the 30
half site preferred COUPTF2 and RXRa (Figure 2D,
right panel). Finally, a similar analysis of 16
H4-SBM-like motifs with all possible permutations at
p10 and p11 conﬁrmed that the H4-SBM xxxCAAAG
TCCA is the only motif recognized by HNF4a speciﬁc-
ally (Supplementary Figure S3).
H4-SBM is bound by HNF4a but not RXRa in vivo
Since the DNA in the PBM does not necessarily have
exactly the same conformation as DNA wrapped in nu-
cleosomes, we determined whether the H4-SBM bound by
HNF4a in vitro is also bound in vivo by analyzing 26
publicly available genome-wide occupancy proﬁles for 14
NRs (Supplementary Table S1). Since data from the same
tissue/cell type were not available for all the NRs and since
we are concerned with binding motifs and not speciﬁc
target genes, we combined and compared ChIP-seq data
for a given NR across different conditions/cell types for
greater statistical power. First, we compared HNF4a
ChIP’ed from mouse liver (48) and RXRa ChIP’ed
from mouse 3T3-L1 (pre-adipocyte) cells (49). In 12097
peaks unique to HNF4a, the motif mined by Gibbs Motif
Sampler (39) was found to be very similar to the H4-SBM,
whereas the motif in 4285 peaks unique to RXRa
was more similar to the canonical DR1 (Figure 3A).
Interestingly, there were 736 ChIP peaks for HNF4a in
liver and RXRa in pre-adipocytes that overlapped; the
motif mined from those peaks had minor variations
from both the H4-SBM and the canonical DR1 but was
nearly identical for RXRa and HNF4a.
We next compared the enrichment of the 16 different
half site sequences with all possible permutations at p10
and p11 in ChIP-seq peaks of RXRa and HNF4a. The
H4-speciﬁc half site sequence AGTCCA had a 2-fold
higher enrichment level compared to control regions
(P=0.001) in the HNF4a peaks but not the RXRa
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Analysis of HNF4a and RXRa ChIP-seq data from mouse liver and
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Figure 3. Continued
error bars. Empirical P values for enrichment levels (*P<0.05,
**P<0.001, ***P<0.0001) are estimated by comparison with the en-
richment levels of 1000 6-nt random genomic sequences. (C)
Enrichment of particular sequences near the center of the HNF4a
and RXRa ChIP-seq peaks described in (A). Distribution of the
indicated DNA sequences containing AGGTCA (left) or AGTCCA
(right) are shown in density plots. The x-axis indicates the distance
(in base pairs) from the peak center. Density plots in black lines are
derived from ﬁve 6-nt random genomic sequences as controls. (D)
Binding polarities of HNF4a and RXRa in vivo. Fold enrichment of
9-nt motifs in the HNF4a and RXRa ChIP peaks described in (A) are
shown in bar plots. Each 9-nt motif contains a 6-nt canonical DR1 half
site or HNF4-speciﬁc half site sequence (underlined) and a 3-nt exten-
sion (p7-p9) that deﬁnes the polarity of the half site [half site sequence
on the 30 side (blue) or the 50 side (red)]. Error bars indicate SD among
multiple data sets.
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half site showed high and comparable enrichment in both
the HNF4a and RXRa peaks. These results suggest that
the H4-speciﬁc half site is preferred by HNF4a but not
RXRa in vivo.
Since ChIP-seq peaks typically cover a region much
larger than the size of a TF binding site, it is frequently
assumed that the binding site of a protein is close to the
peak center (peak summit). Therefore, we compared the
distance from the peak center to the canonical and
HNF4-speciﬁc half site in the ChIP peaks. In both the
HNF4a and RXRa peaks, the canonical half site AGGT
CA was signiﬁcantly enriched around the peak center
compared to random sequences (P<0.001); adding 1nt
at a time to the 50 side of the motif signiﬁcantly increased
the enrichment (Figure 3C, left panels). In contrast, when
the HNF4-speciﬁc half site was analyzed, the enrichment
was observed in HNF4a peaks but not the RXRa peaks
(right panels), conﬁrming that the H4-SBM (CAAAG
TCCA) is bound in vivo by HNF4a but not RXRa.
Finally, in order to determine whether there was any
evidence of half site polarity in vivo, the enrichment
levels of 9-mer sequences with the canonical (AGGTCA)
and the HNF4-speciﬁc (AGTCCA) half site on both the 50
and 30 side were compared in the HNF4a and RXRa
ChIP-seq peaks. HNF4a had a clear preference for the
30 side for both half site sequences (Figure 3D, left
panel, blue versus red bars). While a similar result was
observed for the canonical half site in the RXRa peaks,
the HNF4-speciﬁc motif was not enriched in either
position for RXRa (right panel). These results further
conﬁrm that AGTCCA is not bound by RXRa in vivo
and that the polarity for the half site preference
observed in the PBM for RXRa and HNF4a is also
observed in vivo.
H4-SBM is exclusive to HNF4a in vivo
To determine whether the H4-SBM is recognized by any
other NR aside from HNF4a, we analyzed ChIP-seq data
from 12 additional NRs that are known to be expressed in
one or more of the same tissues as HNF4a—PPARg
(NR1C3) (46,49,50), PPARd (NR1C2) (51), VDR
(NR1I1) (52), FXRa (NR1H4) (53,54), PXR (NR1I2)
(55), ERRb (NR3B2) (56), RARa (NR1B1) (57), ERa
(NR3A1) (58), LXRb (NR1H2) (59), LRH-1 (NR5A2)
(60), Rev-Erba (NR1D1) (61). The glucocorticoid
receptor (GR, NR3C1) (46,62,63), which prefers a differ-
ent half site AGAACA (64,65), served as a negative
control (Supplementary Figure S4A). Motifs of consensus
sequences derived from the 12 NR ChIP-seq peaks did not
reveal any binding to the H4-SBM (Supplementary Figure
S4B). When 6-mer half site sequences were examined, the
H4-speciﬁc half site (AGTCCA) was found to be enriched
in PXR peaks but not in peaks for the remaining 11 NRs
(Figure 4A and Supplementary Figure S5). In contrast,
there was an enrichment of the canonical half site AGG
TCA in 8 of the 12 NRs (Supplementary Figure S5), which
served as a positive control. We also examined the half site
sequences as a function of distance from the peak center.
There was an enrichment in AGGTCA at the peak center
for all tested NRs except GR. The HNF4-speciﬁc half site,
however, was only enriched in peak centers for HNF4a
and three other NRs: Rev-Erba, FXRa and PXR
(Supplementary Figure S6).
Since searching with the 6-mer (AGTCCA) does not
provide any information about its position within a
13-nt motif (i.e. 50 or 30 side), the search was repeated
with the 9-mer H4-SBM (CAAAGTCCA). We found a
13.5-fold enrichment in HNF4a peaks and a considerable
enrichment (>3-fold) in FXRa, PXR and Rev-Erba
peaks; the remaining NRs continued to show no enrich-
ment (Figure 4B). Furthermore, the ChIP-seq peaks for
FXRa, PXR and Rev-Erba ChIP-seq showed consider-
able overlap with HNF4a peaks (Figure 4C and
Supplementary Table S5). Since ChIP cannot distinguish
between direct and indirect binding, it was possible that
FXRa, PXR and Rev-Erba were binding to the H4-SBM
through HNF4a. To address this, we compared the en-
richment level of the HNF4-speciﬁc half site (AGTCCA)
and the full H4-SBM (CAAAGTCCA) in the peaks of
each of the three NRs that overlapped with the HNF4a
peaks to those that did not overlap. If a particular
sequence is a direct binding target of a NR, then similar
enrichment levels are expected in both overlapping (sector
C) and non-overlapping peaks (sector A) (Figure 4D, left).
On the other hand, if the NR requires HNF4a to bind
the sequence, then the overlapping peaks should have
a higher enrichment level than the non-overlapping peak
(Figure 4D, right). The results show that both AGTCCA
and CAAAGTCCA are enriched in the overlapping peaks
but not the non-overlapping peaks for all three NRs
(Figure 4E). The fold enrichment for H4-SBM was in
fact 3- to 6-fold higher in the overlapping peaks
compared to the non-overlapping peaks. Furthermore,
the HNF4-speciﬁc half site was the only 1 of 16 candidate
6-mers that showed such an enrichment for these NRs
(Supplementary Figure S7C). A similar analysis with the
peaks unique to HNF4a (sector B) veriﬁed the method-
ology (Supplementary Figures S7B and S7D). These
results suggest that while PXR, FXRa and Rev-Erba are
localized to regions in the genome that contain the
HNF4-speciﬁc motif, they may do so only when HNF4a
is also present in the same region. While we cannot deﬁni-
tively rule out direct interactions between these NRs and
HNF4a, AGGTCA-like motifs were found in about half
of the overlapping peaks that contain the H4-SBM
(Supplementary Figure S7E–S7H). This suggests that
PXR, FXRa and Rev-Erba may bind canonical AGGT
CA-containing motifs cooperatively with HNF4a in
regions that contain the H4-SBM. For example, on the
Cyp7a1 promoter there are overlapping ChIP-seq peaks
for HNF4a, PXR and Rev-Erba but the only H4-SBM
is at the center of the HNF4a peak (Supplementary
Figure S7I).
HNF4-speciﬁc DNA recognition is mediated by two
residues in the DBD, Asp69 and Arg76
To determine the molecular basis of HNF4-speciﬁc DNA
recognition, protein–DNA interactions were analyzed in
the DBD structures of HNF4a and RXRa (66,67).
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only four residues differ between RXRa and HNF4a.I n
HNF4a, two of these residues, Asp69 and Arg76, lie in the
ﬁrst DNA recognition helix of the DBD and interact with
side chains of nucleotides at p3 and p4 in both half sites of
the DR1 motif (Figure 5A). These two residues are com-
pletely conserved in HNF4 genes across all species from
human down to Trichoplax, except for Caenorhabditis
elegans which contains  260 HNF4-like genes
(Supplementary Figure S8A). Residues at equivalent
positions in RXRa and COUPTF2 are Glu and Lys, re-
spectively (Figure 5B).
To examine the effect of Asp69 and Arg76 on HNF4a
binding speciﬁcity, single and double point mutations
D69E, R76K and D69E/R76K were introduced into the
HNF4a DBD to convert it into an RXR/COUPTF2-like
DBD. In the PBM, the D69E mutant selectively abolished
binding to the H4-SBM while R76K seemed to decrease
binding in a non-selective fashion; interestingly, the
double mutant D69E/R76K yielded a proﬁle nearly iden-
tical to that of D69E (Supplementary Figure S8B), sug-
gesting that both Asp69 and Arg76 are necessary for
optimal discrimination between H4-SBM and other sites.
Importantly, the HNF4a D69E/R76K double mutant also
altered the binding proﬁle to more closely resemble that of
RXRa/COUPTF2; none of the HNF4-speciﬁc binders
were bound by the double mutant (Figure 5C and D).
While some common binders of HNF4a and RXRa/
COUPTF2 were also affected by the mutations
(Supplementary Figure S8C and S8D), most of them
bear the AGTTCA motif in the 30 half site that is also
preferred by HNF4a but not RXRa in vivo (Figure 3B).
Finally, HNF4a and HNF4g are the only human NRs
with an aspartic acid at residue 69 and an arginine at
residue 76 [Figure 5B and (7)], suggesting that the
H4-SBM may be truly speciﬁc to HNF4 in the entire
NR superfamily.
HNF4a activates gene expression using
HNF4-speciﬁc binding sites
To determine whether the HNF4a binding site preference
results in a functional outcome (i.e. gene expression),
luciferase reporter assays were performed using a known
HNF4a/RXRa response element from the human APOA1
promoter. As predicted, HNF4a activated gene expres-
sion using both the wild-type response element (WT-RE)
AGGGCAgGGGTCA and an HNF4-speciﬁc mutant
(MUT-RE) AGTCCAgGGTCCA; in contrast RXRa
activated expression only from the WT-RE (Figure 6A).
In addition, COUPTF2, a repressor, competed with
Figure 4. Comparison of in vivo DNA binding speciﬁcity of multiple NRs. (A) Fold enrichment of the canonical DR1 half site sequence (blue) and
the HNF4-speciﬁc half site sequence (red) in ChIP peaks of 14 NRs. ChIP-seq data for different isoforms of a NR or multiple data sets for the same
protein are combined (see Supplementary Table S1 and text for references); SD is indicated by error bars. Empirical P values for enrichment levels
(*P<0.05, ** P<0.001, *** P<0.0001) are estimated using enrichment levels compared to 1000 6-nt random genomic sequences. Only P values for
AGTCCA are indicated. (See Supplementary Figure S5 for enrichment values for 14 additional half site sequences.). (B) Fold enrichment in ChIP-seq
peaks of 14 NRs as in (A) but for the H4-SBM. P values are estimated using 1000 9-nt random genomic sequences. (C) Overlap between
ChIP-seq peaks among select NRs in mouse liver. Given is the percent of overlapping ChIP-seq peaks between the NRs indicated on the top
and the side. For example, 59.6% of FXRa peaks overlap with HNF4a peaks, while only 32.2% of HNF4a peaks overlap with FXRa peaks.
(D) Schematic representation of direct and indirect binding of a NR to the H4-SBM. Left: direct binding to the H4-SBM is characterized by the even
distribution of H4-SBM sites in overlapping and non-overlapping peaks (sectors C and A, respectively). Right: indirect binding of a NR to the
H4-SBM via HNF4a would yield a greater number of H4-SBM sites in the overlapping peaks. (E) Enrichment of the HNF4-speciﬁc half site (left)
and the H4-SBM (right) in ChIP-seq peaks for the indicated NRs as described in (C). Blue bars indicate fold enrichment in non-overlapping peaks
with HNF4a ChIP-seq peaks (sector A). Red bars indicate fold enrichment in overlapping peaks with HNF4a ChIP-seq peaks (sector C). P values
[as in (A)] are estimated using ratios of 1000 6- and 9-nt random genomic sequences, respectively, for two analyzed motifs.
Nucleic Acids Research, 2012,Vol.40, No. 12 5349HNF4a on the WT-RE but not the MUT-RE (Figure 6B).
These results verify that HNF4a is capable of activating
gene expression using the H4-SBM, while RXRa and
COUPTF2 cannot functionally compete with HNF4a
for the H4-SBM response element.
The effect of the D69E mutation was also examined in
the luciferase assay using an endogenous promoter from a
known HNF4a target gene, APOC2 (31). WT HNF4a
successfully activated the expression of the WT
promoter containing an AGGCCAaAGTCCT motif
whereas the D69E mutant failed to do so (Figure 6C).
In contrast, both the WT and D69E mutant activated
gene expression when the H4-speciﬁc response element
was mutated to a more canonical DR1 element AGGCC
AaAGGTCT (Figure 6C, reverse complement sequences
hApoA1.WT
hHNF4α2
+
-
-
-
+
-
+
-
+
-
-
+ hRXRα/9cisRA
hApoA1.MUT
-
+
-
-
-
+
+
-
-
+
-
+
N
o
r
m
a
l
i
z
e
d
 
R
L
U
(
x
1
0
,
0
0
0
)
hApoC2.WT
hHNF4α2 WT
hApoC2.MUT
hHNF4α2 D69E
+
-
-
-
+
-
+
-
+
-
-
+
-
+
-
+
-
+
+
-
-
+
-
-
N
o
r
m
a
l
i
z
e
d
 
R
L
U
(
x
1
0
,
0
0
0
)
+
-
-
-
+
-
-
+
+
-
+
-
+
-
+
+
-
+
-
+
-
-
-
+
-
+
-
+
+
-
+
+
-
+
+
-
hApoA1.WT
hHNF4α2
hApoA1.MUT
hCOUPTF2
N
o
r
m
a
l
i
z
e
d
 
R
L
U
(
x
1
0
,
0
0
0
)
AGGGCAgGGGTCA
AGTCCAgGGTCCA
Luc hAPOA1-DR1
WT
MUT
TATA
AGGACTtTGGCCT
AGACCTtTGGCCT
-115 +18
Luc hAPOC2
WT
MUT
B
C
A
Figure 6. Speciﬁcity of the HNF4-speciﬁc binding motif in cell-based
reporter gene assays. (A) Luciferase reporter assay in HEK293T cells
co-transfected with 500ng of indicated reporter construct
(pGL4.23.hApoA1.DR1.WT or pGL4.23.hApoA1.DR1.MUT) plus
50ng of expression vector (+, pcDNA3.1.hHNF4a2o r
pMT2.hRXRa) or empty vector ( , pcDNA3.1). 9-cis-retinoic acid
(1mM) (or ethanol as vehicle control) was added as indicated. Right:
diagram of the wild-type (WT) and mutated (MUT) response elements
in the reporter construct for (A) and (B). Shown are relative light units
(RLU) normalized to b-galactosidase activity. Bars are average of
three replicates. Error bars indicate SEM. (B) As in (A) but with
the expression vector (+, pcDNA3.1.hHNF4a) and two different
amounts of pMT2.hCOUPTF2 (400 and 800ng). Empty vector
was added to adjust for amount of total DNA transfected. (C)A s
in (A) but with the indicated reporter constructs (pGL4.10.hAPOC2.
WT or pGL4.10.hAPOC2.MUT) plus the expression vector (+,
pcDNA3.1hHNF4a or pcDNA3.1hHNF4a.D69E carrying the D69E
mutation in its DBD). Right: diagram of the WT and MUT
hHNF4a response element in the human APOC2 promoter.
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Figure 5. Molecular basis of HNF4-speciﬁc DNA recognition. (A)
Superimposed crystal structures of HNF4a DBD (3CBB, cyan) and
RXRa DBD (1BY4, yellow). In the HNF4a structure, only D69 and
R76 interact with the third and fourth base pairs of the AGTCCA half
site. The equivalent residues of RXRa are E and K, respectively.
(B) Sequence alignment of the indicated human NRs in the DNA rec-
ognition helix of the ﬁrst zinc ﬁnger. Numbers 69 and 76 refer to
the residues in human HNF4a2. (C) Scatter plots of PBM data as in
Figure 2A of the WT and mutant HNF4a compared to WT RXRa.
Binding sequences speciﬁc to HNF4a WT are indicated as red spots.
All the red spots shift to the non-binding quadrant in the HNF4a
double mutant D69E/R76K. (D) As in (C) but comparison of
HNF4aWT and D69E/R76K mutant to COUPTF2.
5350 Nucleic Acids Research, 2012,Vol.40, No. 12are shown in the ﬁgure to maintain the orientation in the
genome). This result conﬁrms that Asp69 is responsible
for the HNF4-speciﬁc DNA binding.
Functionality of HNF4-speciﬁc binding sequences in vivo
In order to determine whether the H4-SBM is functional
under physiological conditions, we trained an SVM model
on  200 veriﬁed H4-SBM sites from the PBM to predict
all 13-nt sequences that can be bound speciﬁcally by
HNF4a (variations in the less conserved positions of the
consensus H4-SBM, CAAAGTCCA, such as p6-p8 and
p13 can be tolerated, Figure 1B). This method generated
 3000 high conﬁdence, predicted HNF4-speciﬁc bind-
ing sequences. (See Supplementary Table S3 for a list of
all H4-SBM sequences and http://nrmotif.ucr.edu/
NRBSScan/H4SBM.htm for a web-based, HNF4-speciﬁc
binding sequence search tool.)
The predicted H4-SBM sites were ﬁrst validated by
comparing their position in ChIP-seq peaks to the
veriﬁed H4-SBM sites and the AGTCCA half site
(Figure 7A). The predicted and veriﬁed H4-SBM sites
Figure 7. Prediction of HNF4-speciﬁc binding sequences and target genes. (A) Distribution of HNF4-speciﬁc binding sequences in HNF4a ChIP-seq
peaks in HepG2 cells (41) are shown in density plots. Red line,  200 HNF4-speciﬁc PBM sites; blue line,  3000 predicted HNF4-speciﬁc sites; green
line, the HNF4-speciﬁc half site sequence; black line, ﬁve 6-nt random genomic sequences used as controls. P value is calculated by the F-test. (B)
Box plots of predicted and veriﬁed HNF4-speciﬁc sites compared to  3000 random sequences in the regulatory regions of human genes ( 10 to
+10kb from TSS). Both the predicted and veriﬁed HNF4-speciﬁc sequences occur at a statistically signiﬁcant high frequency compared to random
sequences (P<0.001 in Student’s t-test). (C) Strategy used to search for potential HNF4-speciﬁc target genes. See text for details. (D) Classiﬁcation
of  100 predicted human HNF4a target genes based on the analysis in (C). All of these genes have at least one HNF4-speciﬁc site in an HNF4a
ChIP-seq peak in HepG2 cells (41) and were down regulated by HNF4a RNAi in HepG2 cells (13). See Supplementary Table S4 for a complete list
of the 137 genes identiﬁed in (C) as well as Gene Ontology results. *, genes previously identiﬁed in (13) as predicted HNF4a target genes but with no
indication of containing an HNF4-speciﬁc binding motif. Nearly all the other genes have not been previously identiﬁed as HNF4a targets.
Nucleic Acids Research, 2012,Vol.40, No. 12 5351were then examined across all protein-coding genes in the
human genome relative to the TSS (+1),  10 to +10kb.
(HNF4 binding sites are symmetrically distributed on
both side of TSS, Supplementary Figure S9). The results
show comparable occurrence frequencies for the predicted
and veriﬁed sites (P>0.05) that were signiﬁcantly higher
than those of random sequences (P<0.001) (Figure 7B).
Finally, we used the predicted H4-SBM sites to search
HNF4a ChIP-seq and expression proﬁling data to
identify potential HNF4a target genes. A total of 730
genes in the human liver cell line HepG2 were found to
have at least one predicted H4-SBM site in a HNF4a
ChIP-seq peak within  10 to+10kb of +1 (Figure 7C).
Among these genes, 137 were down-regulated by HNF4a
RNA interference (RNAi) in HepG2 cells (13), suggesting
that these genes are direct targets of HNF4a. GO analysis
showed that the H4-speciﬁc genes were enriched in a
variety of metabolic processes (e.g. lipid, carbohydrate,
xenobiotic/drug metabolic processes; homeostasis; trans-
port), typical of classical HNF4a targets (Supplementary
Table S3). There were also genes in some of the new
categories of HNF4a targets that we identiﬁed in our
previous study (13), such as immune response, signal
transduction, apoptosis and cell structure (Figure 7D).
That study, however, did not identify HNF4-speciﬁc
motifs or targets. All told, this analysis identiﬁed  100
new predicted, direct HNF4a target genes that have an
H4-SBM in a ChIP peak and are down regulated by an
HNF4a RNAi.
Interestingly, several genes associated with acyl Co-
enzyme A metabolism (acyl-CoA synthases, thioesterases,
ligases and a co-factor for a desaturase) were identiﬁed as
putative HNF4a targets with an H4-SBM site (ACSM2B,
EHHADH, ACOT2, ACSF2, SLC27A2, CYB5A, AGXT).
Others have shown that HNF4a binds not only acyl Co-A
binding protein but also fatty acyl thioesters of
Co-enzyme A that appear to act as modulators of
HNF4a function (68–70). Acyl Co-A is well known for
donating an acetate group in acetylation reactions of
lipids and proteins. HNF4a itself has been shown to be
acetylated in its hinge region (71), as have many of the
enzymes encoded by HNF4a target genes—e.g. PEPCK
(PCK1), a classical HNF4a target (72) that catalyzes
the rate limiting step in gluconeogenesis, and the new
H4-SBM target reported here, EHHADH, which
encodes enoyl–coenzyme A hydratase/3-hydroxyacyl–
coenzyme A that catalyzes two steps in fatty acid oxida-
tion (73). While it is not only possible but very likely that
these H4-SBM genes are also regulated by other TFs,
including other NRs via other sites in the promoters,
these results nonetheless reinforce the notion that there
is an important relationship between HNF4a and
processes involving Co-enzyme A. Finally, we note that
several of the newly identiﬁed H4-SBM containing
HNF4a target genes are linked to human diseases
(LIPA, EHHADH, AGXT, PIPOX, HGD, CYB5A,
PDZK1, F11), expanding the clinical relevance of
HNF4a. (See Supplementary Table S3 for a complete
list of H4-SBM target genes from both a  10 to+10kb
and a  2 to+1kb analysis.)
DISCUSSION
The dogma in the NR ﬁeld is that NRs recognize DNA
targets based on one of two motif modules, AGGTCA
(non-steroid receptors plus ER) and AGAACA (all
other steroid receptors) (Figure 8A). While there are add-
itional rules for spacing and orientation [as well as some
variations on the half site motif, such as AGTTCA (7)]
that distinguish the different receptors, those rules do not
adequately explain the diversity of NR function in vivo.
We addressed this issue by comparing the binding speciﬁ-
city of three highly related NRs—HNF4a, RXRa and
COUPTF2—on  3000 different variations of a canonical
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Figure 8. New insights into NR DNA binding from PBM and
ChIP-seq analysis. (A) Half site motif for the indicated NRs along
with the amino acid sequence of the P box region in the DNA recog-
nition helix of the ﬁrst zinc ﬁnger in the DBD showing the residues
relevant to this work. GR, MR, AR and PR: glucocorticoid, mineralo-
corticoid, androgen and progesterone receptors, respectively). The only
NRs that have P boxes that are not depicted are TLX (NR2E1) with an
Asp (D) and Lys (K) and PNR (NR2E3) with an Asn (N) and Lys (K)
at positions 69 and 76, respectively (HNF4a numbering). (B) RXRa,
COUPTF2 and HNF4a homodimers all bind classical DR1-like motifs
(AGGTCAxAGGTCA) while HNF4a homodimers also bind an
HNF4-speciﬁc binding motif (H4-SBM, xxxxCAAAGTCCA) that is
not bound by RXRa or COUPTF2 in the PBMs, nor 11 other NRs
in ChIP-seq. (C) RXRa has a preference for the 30 half site in a
DR1-like motif in RXR:RXR homodimers as well as in RXR:RAR
and RXR:PPAR homodimers, suggesting that an exchange between the
50 RXRa monomer and RAR or PPAR monomers could occur without
disrupting the binding of the 30 RXRa monomer. COUPTF2 also
prefers the 30 half site of the DR1-like motifs, suggesting it could
compete with RXRa homo- or heterodimers on these response
elements. (D) PXR, FXRa and RevErba ChIP peaks from mouse
liver were all found to be enriched for the H4-SBM but only in the
presence of HNF4a, suggesting that they may occupy their own
binding sites near HNF4a-bound H4-SBM.
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receptors in crude nuclear extracts. We identify a new
motif module for HNF4a, AGTCCA and provide add-
itional insight into NR DNA binding (Figure 8A–D).
NR DNA binding polarity
In contrast to most gel shift results, including our own
(27), we observed excellent binding of RXRa in the
PBM in the absence of an ectopically expressed partner.
The RXRa binding was nearly identical to that of
COUPTF2, and both receptors exhibited a polarity
in binding with a preference for the 30 half site of the
DR1 (Figure 8B and C). To our knowledge, this is
the ﬁrst report to examine polarity in DNA binding
using PBMs, and the ﬁrst report of polarity for NR
homodimers. Since RXRa homodimers can activate tran-
scription in the presence of the 9-cis retinoic acid and since
COUPTF2 generally represses transcription, this suggests
that the competition already observed between these two
NRs on a few genes may in fact be a much broader
phenomenon.
While binding polarities of NR homodimers have not
been reported previously, the concept in heterodimers is
not new. For example, RXR binds the 50 half site in DR3,
DR4 and DR5 motifs as heterodimers with VDR, TR and
RAR, respectively (74–76). This polarity was also noted in
crystal and solution structures of RXR heterodimers with
RAR and VDR (77,78). However, on DR1 motifs the
polarity of the RXR heterodimers is reversed with RXR
in heterodimers with RAR and PPAR occupying the 30
half site in DR1 motifs (78–82). Since our results now
show that the RXRa homodimer also prefers the 30 half
site in DR1-like motifs, this suggests that there could be
an exchange between the 50 RXRa monomer in the
homodimer and PPAR or RAR monomers (Figure 8C).
The net result would be a replacement of the RXRa
homodimer with a heterodimeric complex, perhaps while
the 30 RXRa monomer remains bound to the DNA. This
would suggest a new paradigm for RXRa dimer exchange
and a potential new role for RXRa homodimers as place-
holders for RXRa heterodimers on DR1-like motifs, but
must be experimentally proven. A thorough analysis of
RXR heterodimer DNA binding speciﬁcity also needs to
be done.
An NR-speciﬁc DNA binding motif
Comparison of the HNF4a PBM results to that of RXRa
and COUPTF2 allowed us to identify in vitro an
HNF4-speciﬁc binding motif (xxxxCAAAGTCCA) that
we had not identiﬁed previously when we analyzed
HNF4a alone (13). In vivo analysis showed that  8 and
42% of HNF4a ChIP-seq peaks contain CAAAGTCCA
and AGTCCA, respectively (motif variations not
considered). Comparable results were observed for CAA
AGGTCA and AGGTCA (Supplementary Figure S10),
suggesting a similar importance of AGGTCA- and
AGTCCA-based motifs for HNF4a binding. The
H4-SBM was not bound by RXRa or COUPTF2 in the
PBM, nor eight other NRs in ChIP-seq data (Figure 8B).
However, three NRs (FXRa, PXR and Rev-Erba) were
associated with the H4-SBM in vivo, most likely via
their own binding sites, not the H4-SBM (Figure 8D).
While there are a few reports of these NRs regulating
the same target genes as HNF4a via their own binding
sites (83–87), our results suggest that this may be a
much broader phenomenon. The considerable overlap
between PXR, FXRa, Rev-Erba and HNF4a peaks in
ChIP-seq data also demonstrates the complexity of
NR-mediated regulation and the difﬁculty of precisely
identifying binding sites for a given TF in ChIP-seq
peaks. This complexity is increased by protein–protein
interactions between HNF4a and other NRs such as
PXR and FXR and competition for co-regulators (12).
Our analysis shows how this problem can be overcome
at least in part with a better understanding of binding
speciﬁcities generated by the PBMs.
While this is the ﬁrst identiﬁcation and genome-wide
analysis of an HNF4-speciﬁc binding motif, there were
previous reports using classical methods suggesting that
such a motif might exist. A survey of the literature
identiﬁed 28 response elements that had been examined
for responsiveness to HNF4a, RXRa and/or COUPTF2.
Six of those elements carry the H4-SBM TC instead of the
DR1-like GT at p10 and p11, and all six were responsive
to HNF4a but not RXRa or COUPTF2. In contrast, the
remaining 22 response elements did not have a TC at
p10-11 and were responsive to RXRa or COUPTF2
(Supplementary Table S2). However, since these ﬁndings
were generated by different groups over a period of years,
an HNF4-speciﬁc motif was never identiﬁed.
In addition to the H4-SBM, we also identiﬁed a pair of
residues in the HNF4 DBD that is responsible for the
H4-SBM binding (Asp69 and Arg76) (Figure 8A).
Asp69, which has the greatest effect on HNF4-speciﬁc
binding, is in the P box which was shown previously to
be responsible for the different half site of GR and related
receptors (AGAACA) (5,88). Arg 76 is in the helix that
contacts the DNA but to our knowledge has not been
previously associated with DNA binding speciﬁcity.
HNF4 is the only human NR with the combination of
Asp69 and Arg76 and all HNF4 DBDs, except some of
the HNF4-like genes in C. elegans, have these residues,
suggesting that the H4-SBM may be truly unique to
HNF4. There is only one other NR that has an Asp
at position 69, TLX (NR2E1), but it also has a Lys at
position 76 instead of an Arg (7). Since the R76K
mutant of HNF4 lost most of its DNA binding activity,
we assume that TLX would not be able to recapitulate
the HNF4-speciﬁc binding, although that remains to be
determined.
Finally, it is of interest to note that HNF4, RXR
and COUPTF are among the most ancient of all the
NRs (9). Since the biologically least complex metazoans
currently in existence all have at least two NR genes
(one HNF4-like and one RXR/COUPTF-like), it has
been proposed that the NR family evolved from a now
extinct early metazoan that contained a single NR gene,
which was most similar to HNF4 (89). Intriguingly, the
HNF4 DBDs of primitive metazoans all have the
Asp69-Arg76 pair of mammalian HNF4.
Nucleic Acids Research, 2012,Vol.40, No. 12 5353In conclusion, our results highlight a complexity of NR
DNA binding speciﬁcity that was previously under
appreciated. They also demonstrate the usefulness of the
PBM approach to more accurately deﬁne that complexity
and thereby more precisely identify NR target genes
in vivo. It will be of interest to compare the binding spe-
ciﬁcity of other NRs in a similar fashion.
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